About

Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life-enhancing biotherapeutics.

Empowering Cell Culture and Process Liquid Workflows

We enable our customers to optimize their workflow and productivity – from basic research to commercial production – to accelerate the development of life-enhancing biotherapeutics.

Our Mission

GeminiBio provides our customers with cell culture products and solutions that accelerate and streamline their discovery, development, and production processes and cGMP bioprocess liquids that radically simplify manufacturing workflows.

Our Company Values 

Doing the right thing – the first time.  Honoring and keeping commitments.

Working with speed and focus to deliver the highest quality results – on time.

Embracing unique perspectives and treating others with dignity and respect. 

Biased to improve processes and products to better serve customers and improve workflows.

GeminiBio’s cGMP Manufacturing Facility 

Est. 1985

/

Located in West Sacramento, California, GeminiBio has two manufacturing facilities, comprising a total of 57,000 square feet. To meet the stringent needs of biotechnology research and production customers, the company’s cell culture sera and bioprocess liquid manufacturing facilities are segregated between animal origin-free cGMP manufacturing and animal component cGMP manufacturing.

 

GeminiBio’s 25,000 square foot facility, located at 920 Stillwater Road, Suite 130, West Sacramento, California, is dedicated to animal origin free (AOF) upstream and downstream media and buffer manufacturing.  The facility includes a range of ISO 7 processing suites, including suites with 500-liter and 1,000-liter single use mixing vessels, and classified manufacturing space with 5,000-liter and 10,000-liter stainless-steel mixing vessels.  Batch sizes span from 10-liters to 10,000-liters and we have the ability to fill aseptically into diverse containment types (rigid and flexible) and sizes (500 mL bottles to 1,000-liter pallet tanks).

 

GeminiBio’s range of bioprocess liquid batch sizes allow the company to support the unique process liquid demands of large-scale monoclonal antibody (mAb) and plasmid DNA manufacturers, the small to mid-size batch requirements of AAV and LVV viral vector manufacturers, as well as the small batch size requirements of Cell Therapy customer’s therapeutic cell manufacturing.

 

GeminiBio’s 32,000 square foot facility, located at 3230 Reed Ave., West Sacramento, California, includes cGMP warehouse space as well as segregated and dedicated animal origin (AO) ISO 7 manufacturing suites.  Our cGMP warehouse includes temperature mapped and validated storage conditions at -20C, 2-8C, and controlled room temperature (CRT).

 

GeminiBio has validated processes related to both the movement and segregation of AOF and AO raw materials and finished goods.  Our AO manufacturing suites are further segregated between human component only and animal origin/ animal component.  Each ISO 7 suite includes a 500-liter single use mixing vessel and can manufacture AO/AC media and serums in batch sizes from 10-liters to 500-liters and ability to fill into diverse container types (rigid and flexible) and sizes (125 mL bottles to 100-liter bags).at -20C, 2-8C, and controlled room temperature (CRT).

Our Integrated Quality Approach

01

Certifications, Registrations and Compliance01

To meet the stringent quality requirements of our customers, GeminiBio is certified to ISO 13485:2016, maintains an FDA registration under Class I Medical Devices, and is aligned with 21 CFR Part 820: Quality System Regulation.

 

 

Learn More
Certifications Registrations and Compliance
02

Manufacturing Design02

GeminiBio’s facilities are designed with current Good Manufacturing Practices (cGMP) and our customer’s quality requirements in mind. Our animal origin free (AOF) manufacturing facility is 1/4 mile away from our animal origin (AO) manufacturing facility. In addition, our cGMP warehouse is designed with flows for both personnel and materials, including segregation of AO and AOF materials.

 

Learn More
Manufacturing Design
03

Risk Management03

GeminiBio has developed a robust and rigorous risk management mitigation program.   Our four-step approach includes Supplier Management, Change Management, Internal Audits governed by ISO 13485:2016, and Customer Audits.

 

 

Learn More
Risk Management

Meet Our Executive Leadership Team

Our Team

Brian Parker

Chief Executive Officer

Ed Mendham

Chief Financial Officer

Rob Perry

Chief Scientific Officer

Justin Henson

EVP - Core Sales & Sales Ops

David Terry

VP-Sales, Process Liquid

Patricia Cazcarro

Vice President Operations

/

Brian Parker

Chief Executive Officer

Ed Mendham

Chief Financial Officer

Rob Perry

Chief Scientific Officer

Justin Henson

EVP - Core Sales & Sales Ops

David Terry

VP-Sales, Process Liquid

Patricia Cazcarro

Vice President Operations

  • Brian Parker joined GeminiBio in July of 2021 and was previously at Thermo Fisher Scientific where he was Vice President and General Manager of the Production Chemicals and Services business unit within the Bioproduction Division.  While leading the Production Chemicals and Services business, Brian reversed two years of negative organic growth by developing and commercializing new products and solutions to better serve global bioproduction customers, as well as expanding the business’ reach into all global regions.

  • Prior to joining Thermo Fisher in 2017, Brian grew, turned around, and started a wide range of healthcare technology and services businesses, including growing US Oncology’s pharmaceutical services business from $133M to $543M, as well as developing and commercializing novel technology and clinical service solutions that enabled primary care physicians and oncologists to manage value-based reimbursement models for Aetna and Integra Connect respectively.

  • Prior to starting his business career, Brian served in the US Army’s 6th Infantry Division as a Military Intelligence Officer.

  • Brian attended the University of Alaska on a military scholarship and earned a BA in History.

  • Ed Mendham, CPA, MBA joined GeminiBio in August 2021 and had previously served as Chief Financial Officer of Simply Beautiful Smiles, a dental service organization with locations in southeastern Pennsylvania and New Jersey.

  • Prior to Simply Beautiful Smiles, he served as Vice President, Finance – Portfolio Companies for BelHealth Investment Partners, supporting the financial due diligence in both portfolio and add-on acquisitions while working directly with portfolio company finance teams to drive liquidity and reporting.

  • Previously, he was Chief Financial Officer of Qforma, a BelHealth portfolio company and global provider of key opinion leader solutions and launch management solutions for the life sciences industry.

  • Prior to Qforma, he served as Vice President, Finance of Advanced Health Media, an industry leading provider of software solutions, sales force logistics and outsourced speaker bureau management for the pharmaceutical industry.

  • Ed graduated from Trenton State College (The College of New Jersey) with a BS in Accountancy and earned his MBA from Rider University.

  • Robert Perry joined GeminiBio in October 2019 as the Chief Operating Officer and moved to the Chief Scientific Officer role in July 2021.  Prior to GeminiBio, Robert was Sr. Director at Atara Biotherapeutics.

  • At Atara, Robert had responsibility for building their state of the art manufacturing facility in Thousand Oaks, CA, briefly led their external manufacturing and established and ran their materials science group.

  • Prior to Atara, Robert was a co-founder and Vice President of Manufacturing and Logistics at Athersys, Inc responsible for technology transfer of technologies into the company, production and international distribution of clinical trial materials for late-stage development cell therapy product.

  • Robert has designed and overseen capital building projects for life sciences companies in excess of $50MM. He is a frequent guest lecturer and has authored multiple book chapters on GMP manufacturing, logistics and regulatory compliance of cell therapy products.

  • Robert earned his BS in Microbiology from CalPoly, San Luis Obispo, CA.

  • Justin Henson joined GeminiBio in September of 2020 and was previously at Thermo Fisher Scientific where he was the Sr. Director of Global Commercial Operations for the Bioproduction Division.

  • Prior to working at Thermo Fisher, he worked at Avantor for 16 years where he held various sales leadership roles including the VP of Sales for North America, overseeing the Production and Research sales teams, and managing business sold directly to biotech and research institutions, as well as through distribution partners.

  • He has earned his Lean Certification, through Villanova University’s Six Sigma Program, and has developed sales operations programs geared toward driving key behaviors and streamlining effectiveness within commercial organizations.  He has developed sales training programs that focus on continuous learning platforms to drive sales effectiveness and develop a technical understanding of the products and markets served.

  • Justin earned a BS in Biomedical Sciences from Texas A&M University.

  • David Terry joined GeminiBio in February of 2023 and was previously at Cytiva where he was a Process Liquid and Buffer Specialist following the Danaher acquisition of Intermountain Life Sciences (ILS). While at Cytiva, David focused on driving  continued growth of the legacy ILS business as well as participating in the overall growth strategy of the Cytiva process liquid division.

  • Prior to the acquisition of Intermountain Life Sciences by Cytiva, David served as a Bioprocess Specialist at ILS playing a major role in the growth of the business leading to the Danaher acquisition in 2021.

  • Before beginning his career in the life sciences industry David played collegiate and professional tennis and functioned as a director of tennis of multiple successful tennis programs around the US.

  • David earned a bachelors degree in criminology from West Virginia State University

  • Patricia Cazcarro joined GeminiBio in October 2020 and was previously the Quality Manager for a FDA cGMP regulated manufacturing plant and was responsible for testing and release (chemistry, microbiology, and packaging specifications), material disposition, auditing, root cause analysis & CAPA in a large-scale manufacturing environment.

  • Patrcia has extensive experience manufacturing cGMP process liquids for the biotechnology industry gained from her time at Millipore Sigma, where she served as Manufacturing Manager for catalog and custom liquids.

  • Prior to joining Millipore Sigma, Patricia was Manager of Molecular Diagnostics at Enzo Clinical Labs, as well as Manager of R&D at Sanofi-Genzyme.

  • Patricia earned a BS in Biology and a MS in Plant Genetics from Iowa State University.

GeminiBio – where passion & purpose align

 

Our talented team is driven by a shared commitment to achieve our mission by working with intensity, integrity, innovation, and involvement. 

 

Learn More

Let’s Keep in Touch

We are committed to helping you optimize your cell culture and process liquid workflows – how can we help you?

 

Contact Us